This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Beth Israel Deaconess Medical Center, Inc., Dana-Farber-Cancer Institute Inc.. Active years: 2026.
Company Filing History:
1 out of 536 
1 out of 1,266 
Years Active: 2026
Title: Alex Toker: Innovator in AKT Inhibition
Introduction
Alex Toker is a prominent inventor based in Dedham, MA (US). He has made significant contributions to the field of cancer research, particularly in the development of innovative therapeutic strategies targeting AKT, a key player in various cellular processes.
Latest Patents
Toker holds a patent for the "Degradation of AKT by conjugation of ATP-competitive AKT inhibitor GDC-0068 with E3 ligase ligands and methods of use." This patent describes bifunctional compounds that comprise a GDC-0068 analog, which binds to AKT isoforms AKT1, AKT2, and AKT3. The compounds also include a degron that binds to an E3 ubiquitin ligase, covalently attached by a linker. The patent outlines pharmaceutical compositions and methods for treating diseases or conditions mediated by dysfunctional AKT activity. He has 1 patent to his name.
Career Highlights
Throughout his career, Alex Toker has worked with esteemed institutions such as Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. His work has focused on advancing cancer therapies and understanding the molecular mechanisms underlying cancer progression.
Collaborations
Toker has collaborated with various professionals in the field, including his coworker Inchul You. Their joint efforts have contributed to the advancement of research in AKT inhibition and its implications for cancer treatment.
Conclusion
Alex Toker is a notable inventor whose work in AKT inhibition has the potential to impact cancer therapies significantly. His innovative approaches and collaborations continue to drive advancements in the field of cancer research.